Finn Willingham

Finn has over 25 years’ experience in business development, marketing and project management roles in the biotechnology and healthcare sectors. In her current role at the Cell and Gene Therapy Catapult, Finn coordinates the Advanced Therapy Treatment Centre (ATTC) Network, a major Innovate UK-funded programme established to help accelerate adoption of Advanced Therapy Medicinal Products (ATMPs) by the UK’s National Health Services. Her interest in ATMPs originated whilst Director of Business Development of a CDMO, working with an array of start-up and established biotech companies developing these innovative products.